このアイテムのアクセス数: 32
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
s41409-025-02508-2.pdf | 1.58 MB | Adobe PDF | 見る/開く |
タイトル: | Myeloablative conditioning in cord blood transplantation for acute myeloid leukemia patients is efficacious only until age 55 |
著者: | Oshima, Shinichiro Arai, Yasuyuki ![]() ![]() ![]() Kondo, Tadakazu Yano, Shingo Hirabayashi, Shigeki Uchida, Naoyuki Onizuka, Makoto Miyakoshi, Shigesaburo Tanaka, Masatsugu Takahashi, Satoshi Hayashi, Masayuki Kawakita, Toshiro Uehara, Yasufumi Ota, Shuichi Izumi, Toru Sawa, Masashi Nishida, Tetsuya Katayama, Yuta Nagafuji, Koji Kato, Koji Ichinohe, Tatsuo Atsuta, Yoshiko Yanada, Masamitsu |
キーワード: | Haematopoietic cell growth factors Risk factors |
発行日: | Jan-2025 |
出版者: | Springer Nature |
誌名: | Bone marrow transplantation |
抄録: | Umbilical cord blood transplantation (CBT) is accepted as an effective treatment for acute myeloid leukemia (AML), and reduced-intensity conditioning (RIC), rather than myeloablative conditioning (MAC) regimens allowed elderly patients to be treated safely. However, appropriate intensities of conditioning regimens are still unclear, especially for middle-aged patients. To compare outcomes after RIC and MAC regimens, we analyzed AML patients aged 16 years or older in the Japanese registry database, who underwent single cord unit CBT between 2010-2019. Median ages of the RIC group (n = 1353) and the MAC group (n = 2101) were 59 and 51 years (P < 0.001), respectively. 5-year overall survival (OS) after MAC was superior to that of RIC (38.3% vs 27.7%, P < 0.001) with lower incidence of relapse (33.9% vs 37.4%, P = 0.029) and better neutrophil engraftment (84.7% vs 75.9%, P < 0.001). Detailed subgroup analysis revealed that age at transplantation is the most important factor affecting 5-year OS in RIC and MAC. This analysis identified a threshold of 55 years, beyond which the superiority of MAC disappeared, irrespective of other factors such as disease status or performance status. In conclusion, RIC may be preferable for patients aged 56 or older in CBT for AML due to higher potential toxicities. |
著作権等: | This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. © The Author(s) 2025 |
URI: | http://hdl.handle.net/2433/292491 |
DOI(出版社版): | 10.1038/s41409-025-02508-2 |
PubMed ID: | 39838078 |
出現コレクション: | 学術雑誌掲載論文等 |

このアイテムは次のライセンスが設定されています: クリエイティブ・コモンズ・ライセンス